Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Actual. osteol ; 14(1): 10-21, Ene - Abr. 2018. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-1116424

ABSTRACT

La suplementación con calcio reduciría, sola o asociada a otra medicación para osteoporosis, la pérdida de masa ósea y el riesgo de fracturas. Sin embargo, su tasa de adherencia es baja debido a la poca tolerancia. Objetivo: comparar la tasa de absorción neta de calcio entre dos formulaciones distintas de carbonato de calcio (500 mg): comprimidos vs. mousse. Material y métodos: 11 pruebas fueron realizadas en mujeres posmenopáusicas de 58,9±3 años. El diseño fue exploratorio abierto, aleatorizado, prospectivo cruzado de fase 4. Intervención: las participantes fueron aleatorizadas en dos grupos para recibir las dos formulaciones previa suplementación con vitamina D3. La tasa de absorción neta de calcio fue estudiada por la prueba de inhibición de hormona paratiroidea (PTH). Se obtuvieron muestras de sangre: basal y en la 1a, 2a y 3a hora posadministración del calcio asignado, y de orina de 2 horas basal y al final de la prueba. Determinaciones bioquímicas: calcio, fósforo, albúmina, 25-hidroxivitamina D y hormona paratiroidea intacta y calciuria. Análisis estadístico: método de los trapecios para calcular el área bajo la curva (AUC) de la concentración de calcio en el tiempo (R Development Core Team (2008). http://www.Rp-project.org) y Anova con dos términos de error para evaluar el efecto secuencia, período y formulación. Resultados: la mayor inhibición de PTH se observó a dos horas de la toma de ambas formulaciones (comprimidos -39,2% vs. mousse -38,0%; p=ns), con similar AUC0-3 h (comprimidos 3,35; IC 95%: 3,32; 3,37 vs. mousse 3,36; IC 95%: 3,33; 3,38). Cuando analizamos tolerancia y preferencias no se observaron diferencias estadísticamente significativas entre ambas formulaciones. Conclusión: el carbonato de calcio en mousse mostró similar tasa de absorción intestinal, preferencia y tolerancia gastrointestinal que en comprimido. (AU)


Calcium supplementation, administered alone or in combination with a specific medication for osteoporosis, would reduce bone mass loss and fracture risk in postmenopausal women. However, the adherence rate to calcium supplements is low, mainly due to low tolerance. Objective: comparisson of net calcium absorption rate between two different pharmaceutical formulations of calcium carbonate (PFCa) in postmenopausal women. Materials and Methods: 11 tests were performed in postmenopausal women aged 58.9±3 yrs. Design: Comparative, randomized, prospective, open-label exploratory crossover study of calcium mousse versus calcium pills. Intervention: Participants were randomized in 2 groups to receive the 2 different PFCa (500mg): pills vs. mousse, with previous vitamin D3 supplementation. The parathyroid hormone (PTH) inhibition test and the area-under-thecurve (AUC) of calcium were analyzed. Blood samples were taken at baseline and 1, 2 and 3 hrs after intake of the assigned PFCa. Urine samples (2hs) were obtained at -baseline, after 2hs of PFCa intake and at the end of the test. Biochemical Determinations: Serum: calcium, phosphorus, albumin, 25-hydroxyvitamin D, and intact PTH. In urine: calcium. Statistical Analysis: The trapezoid rule was applied to assess AUC in time (R Development Core Team (2008). http://www.Rp-project.org). An ANOVA model with 2 error terms was used to assess the effect of sequence, period, and formulation. Results: The highest inhibition PTH rates were observed after 2 hrs of PFCa (pills -39.2% vs. mousse -38.0%; p=ns). The AUC0-3hrs for both PFCa was similar (pills 3.35; 95%CI: 3.32; 3.37 vs. mousse 3.36; 95%CI: 3.33; 3.38). No statistically significant differences were observed when we analyze tolerance and predilection. Conclusion: The calcium carbonate in mousse showed an adequate rate of intestinal absorption, similarly predilection and gastrointestinal tolerance than the pill presentation. (AU)


Subject(s)
Humans , Female , Middle Aged , Calcium Carbonate/pharmacokinetics , Osteoporosis, Postmenopausal/prevention & control , Calcium/pharmacokinetics , Parathyroid Hormone/analysis , Achlorhydria , Calcitriol/pharmacokinetics , Calcium Carbonate/administration & dosage , Calcium Carbonate/therapeutic use , Body Mass Index , Bone Density , Nutrition Assessment , Osteoporosis, Postmenopausal/diet therapy , Osteoporosis, Postmenopausal/drug therapy , Mass Screening , Calcium/deficiency , Postmenopause/drug effects , Postmenopause/blood , Cholecalciferol/administration & dosage , Cholecalciferol/adverse effects , Cross-Over Studies , Calcium Citrate/therapeutic use , Fractures, Bone/prevention & control , Estrogens/deficiency , Gastrointestinal Absorption/drug effects , Treatment Adherence and Compliance , Anabolic Agents/therapeutic use
2.
Rev. ciênc. farm. básica apl ; 28(2): 177-183, 2007. tab
Article in Portuguese | LILACS | ID: lil-486508

ABSTRACT

A osteoporose é definida pela Organização Mundial de Saúde como uma doença metabólica óssea sistêmica, caracterizada por diminuição da massa óssea e deterioração da microarquitetura do tecido ósseo, com consequente aumento da fragilidade do osso e da suscetibilidade a fraturas. A suplementação de cálcio pode ser realizada utilizando-se diferentes sais de cálcio. O mais recomendado é o carbonato de cálcio, que apresenta a maior quantidade de cálcio elementar (40%). Atualmente, quando todos os caminhos levam à busca da qualidade total, torna-se indispensável conhecer perfeitamente cada fase de um processo produtivo. Neste caso, a validação é uma ferramenta da qualidade adequada para garantir a confiabilidade e reprodutibilidade de um método analítico, pois é um ato documentado que atesta que o mesmo conduz a resultados esperados. A escolha de uma metodologia é de fundamental importância para o procedimento do controle de qualidade da substância ativa ou da forma farmacêutica. Desta forma, o presente estudo teve por objetivo desenvolver e validar o método de doseamento da matéria-prima carbonato de cálcio por titulometria. As características de desempenho investigadas no processo de validação foram: exatidão, precisão, limitede detecção, limite de quantificação, linearidade e robustez. Os resultados obtidos demonstraram que o método é robusto, exato e preciso, apresentando resultados reprodutíveis e confiáveis.


Subject(s)
Calcium Carbonate/pharmacokinetics , Titrimetry/methods , Validation Study
4.
Rev. méd. Chile ; 124(11): 1325-33, nov. 1996. tab, graf
Article in Spanish | LILACS | ID: lil-194500

ABSTRACT

Hydrochloric acid was added to destilled water in increasing amounts to obtain a final pH of 6.9, 3.0, 2.5, 2.0 and 1.5. Eighteen commercial calcium preparations were incubated in these solutions for 60 min and dissolution velocity was measured as the percentage of elemental calcium found in solution after this incubation period. Calcium carbonate preparations had a pH 1.5. Using the solution with pH 1.5 the dissolution velocity of different preparations varied widely from 56 to 100 percent. Calcium acetate, followed by calcium citrate and dicalcic phosphate were the salts in tablets with better dissolution velocities. Among powders and effervescent preparations, those containing calcium lactogluconate and citrate had the better dissolution velocities (95 to 115 percent), that were independent of the solution's pH. A studied preparation with integral bone had a very low dissolution velocity, not surpassing 33 mg of calcium per tablet. The dissolution velocity of different calcium carbonate preparations varies greatly and in conditions of achlorhydria, it is negligible. Calcium lactogluconate and citrate dissolution velocities are independent of the solution's pH


Subject(s)
Tablets/analysis , Calcium/pharmacokinetics , In Vitro Techniques , Calcium Carbonate/pharmacokinetics , Calcium, Dietary/standards , Nutritional Requirements
SELECTION OF CITATIONS
SEARCH DETAIL